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Abstract
Background: The percentage of hypertrophic cardiomyopathy (HCM) patients who are in high
risk for Sudden Death (SD) constitutes only a minority of all HCM population but the incidence of
SD in this subset is high (at least 5% annually). The identification of this small but important
proportion of high risk HCM patients has been the clue in the clinical evaluation of these patients.
Methods: Our study cohort consisted from 123 patients with HCM who are currently followed
up in our Institution. Five clinical risk factors were assessed: a family history of premature SD,
unexplained syncope, Non Sustained Ventricular Tachycardia (NSVT) on 24-h ECG monitoring,
Abnormal Blood Pressure Response (ABPR) during upright exercise testing and Maximum left
ventricular Wall Thickness (MWT) ≥30 mm. The purpose of our study was the identification of
high risk HCM patients coming from Northern Greece.
Results: Fifteen patients (12.2%) of the whole cohort had MWT ≥ 30 mm, 30 patients (24.4%) had
an ABPR to exercise, 17 patients (13.8%) had episodes of NSVT in 24-h Holter monitoring, 17
patients (13.8%) suffered from syncope, and 8 patients (6.5%) had a positive family history of
premature SD. Data analysis revealed that 74 patients (60.1%) had none risk factor. Twenty four
patients (19.5%) had 1 risk factor, 17 patients (13.8%) had 2 risk factors, 4 patients (3.25%) had 3
risk factors, and 4 patients (3.25%) had 4 risk factors, while none patient had 5 risk factors. Twenty
five patients (20.3%) had 2 or more risk factors.
Conclusion: This study for the first time confirms that, although a 60% of patients with HCM
coming from a regional Greek population are in low risk for SD, a substantial proportion (almost
20%) carries a high risk for SD justifying prophylactic therapy with amiodaron or ICD implantation.
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Background
Hypertrophic Cardiomyopathy (HCM) is a genetically
transmitted cardiac disease characterized by myocardial
hypertrophy in the absence of any other cause capable of
producing the magnitude of hypertrophy present [1]. The
incidence of HCM in general population is 0.2% [2]. The
clinical spectrum of the disease is diverse ranging from an
asymptomatic course throughout life to severe heart fail-
ure, stroke or sudden cardiac death [1]. HCM is the most
common cause of sudden death (SD) in young people,
including trained athletes [3]. The percentage of HCM
patients who are in high risk for SD constitutes only a
minority of all HCM population [4] but the incidence of
SD in this subset is high (at least 5% annually) [5]. The
identification of this small but important proportion of
high risk HCM patients has been the clue in the clinical
evaluation of these patients [4,6-8].
Highest risk for SD in HCM has been associated with any
of the following noninvasive clinical markers [4,6,7,9-
11]: prior cardiac arrest or spontaneous sustained ven-
tricular tachycardia; family history of premature SD; syn-
cope; nonsustained ventricular tachycardia (NSVT) on
ambulatory (Holter) ECG recordings; abnormal blood
pressure response (ABPR) to exercise; and extreme left
ventricular (LV) hypertrophy with maximum wall thick-
ness (MWT) ≥30 mm. Northern Greece has a population
of about 3 million. People affected by HCM, in this area,
are estimated to be 6.000. Concentrated epidemiologic
and clinical data concerning the risk of SD and the natural
history of HCM in this area are lacking. The purpose of
our study was the identification of high risk HCM patients
coming from Northern Greece.
Methods
The study cohort consisted from 123 patients with HCM
who are currently followed up in our Institution, and who
completed all noninvasive clinical tests for risk stratifica-
tion, ie, personal and family history, clinical evaluation,
12-lead ECG, transthoracic echocardiography, 24-h ECG
monitoring, and symptom-limited upright exercise test.
Patients with documented sustained ventricular tachycar-
dia or out-of-hospital cardiac arrest and those who were
on amiodarone at first evaluation were excluded. Patients'
follow up commenced the time the first diagnosis was
made even if the diagnosis preceded baseline patient eval-
uation in our clinic. The diagnosis of HCM was based on
the echocardiographic appearance of left ventricular MWT
greater or equal than 15 mm, in the absence of any other
cause capable of producing such hypertrophy [12,13].
HCM was also considered present in patients with MWT
13 or 14 mm in the presence of a positive family history
for HCM and/or ECG changes compatible with HCM. The
patients were evaluated every 12 months, except other-
wise was indicated.
Echocardiography
Echocardiographic studies were performed using a GE
Vingmed Vivid 7 system (GE Vingmed Ultrasound AS,
Horten, Norway). Echocardiographic examination
included M-mode, two-dimensional, pulsed- and contin-
uous-wave Doppler echocardiography, and Tissue Dop-
pler Imaging since the time it was available in our clinic.
Segmental left ventricular hypertrophy was measured in
two-dimensional echocardiography parasternal short axis
views according to previous described methods [13].
Standard M-mode measurements were made according to
the recommendations of the American Society of Echocar-
diography [14]. Basal subaortic gradient was measured by
continuous wave Doppler echocardiography [15].
Stress test
Patients underwent symptom-limited upright exercise test
using the Bruce protocol in a Schiller AT-6C Stress Test
Treadmill System. Blood pressure was measured using a
mercury sphygmomanometer and auscultation of the
Korotkoff sounds over the brachial artery at rest, every
minute during exercise and for the first 3 min of recovery
Holter monitoring
All patients underwent-24 h ECG monitoring (using vari-
ous systems commercially available) while performing
ordinary daily activities.
Definitions
Syncope
A history of syncope was defined as one or more episodes
of unexplained loss of consciousness preceding patients'
first visit to our Hospital.
Premature sudden death
A family history of premature SD was defined as SD in one
or more first-degree relatives <50 years old.
Non-sustained ventricular tachycardia
NSVT was defined as a run of three or more consecutive
ventricular beats at a rate of ≥120 beats/min, lasting <30 s.
Abnormal blood pressure response
An ABPR was defined as a failure of systolic blood pres-
sure to rise more than 20 mmHg, or a fall of systolic blood
pressure, during exercise.
Risk factors
Five clinical risk factors were assessed: a family history of
premature SD, unexplained syncope, NSVT on 24-h ECG
monitoring, ABPR during upright exercise testing and left
ventricular MWT ≥30 mm.Cardiovascular Ultrasound 2009, 7:37 http://www.cardiovascularultrasound.com/content/7/1/37
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Statistical analysis
Normality plots were tested using Kolmogorov-Smirnoff
test for a p value > 0.05. Distributions of variables in the
study cohort are summarized as means ± SD and as medi-
ans (IQR) for non-normally distributed data. Percentages
are also reported. Most of the statistical estimates were
performed using the Statistical Package for Social Sciences
version 17.0 (SPSS, Chicago, Illinois).
Results
Demographic and clinical characteristics of the 123
patients are outlined in Table 1. Patients' age at initial
evaluation was 52.3 ± 15.6 years (16 to 83 years). Patients'
mean age at the time of first diagnosis was 48.3 ± 16.4 (5
to 81 years), 82 patients (66.6%) were male. Nine patients
(7.3%) were diagnosed as having HCM with congestive
evolution. The diagnosis of congestive form was based on
echocardiographic appearance of left ventricular MWT
greater or equal than 15 mm with reduced ejection frac-
tion (<50%) in the absence of any cause of secondary
hypertrophy. In 3 patients the diagnosis confirmed by
myocardial biopsy (extended myocardial disarray with
hypertrophied myofibrils and areas of fibrosis). Coronary
angiography and left heart catheterization was also per-
formed in the remaining patients with HCM and systolic
impairment. All these patients had normal coronaries
without any valvulopathy more than moderate in severity.
Coronary artery disease confirmed by coronary angiogra-
phy was present in 6 patients (4.8%).
Echocardiographic data
The mean value of LV end-diastolic diameter was 4.32 ±
0.79 cm (range 2.77 to 7.05 cm), and the mean value of
LV Ejection Fraction was 71.7 ± 13% (30 to 90%). The
mean value of MWT was 2.16 ± 0.57 cm (range 1.42 to
3.87 cm) and the mean value of left atrial size was 4.09 ±
0.68 cm (range 2.24 to 5.90 cm). Twenty seven patients
(21.9%) had resting subaortic gradient ≥30 mmHg (range
32 to 230 mmHg). Fifteen patients (12.2%) had maxi-
mum wall thickness ≥30 mm. The above data are outlined
in Table 2.
Medical treatment
Sixty five percent of our patients were on medication at
the initial or started after that. The patients mainly
received b-blockers (47.9%). Amiodaron was started after
first evaluation in our Institution. Thirty five percent were
not on any medication. The above data are outlined in
Table 3.
Risk Factors
Fifteen patients (12.2%) of the whole cohort had MWT ≥
30 mm, 30 patients (24.4%) had an ABPR to exercise, 17
patients (13.8%) had episodes of NSVT in 24-h Holter
monitoring, 17 patients (13.8%) suffered from syncope,
Table 1: Demographic and clinical characteristics of 123 patients 
with Hypertrophic Cardiomyopathy.
Age, years 52.3 ± 15.6 (16 to 83)
Age of initial diagnosis, years 48.3 ± 16.4 (5 to 81)
Male gender 82 (66.6%)
Referral patients 68 (55.8%)
Non-referral patients 55 (44.7%)
Clinical status
Asymptomatic 56(45.5%)
Symptomatic 67 (54.5%)
Patients with NYHA class II 52 (42.2%)
Patients with NYHA class III/IV 15(12.1%)
Family history of premature SD 8 (6.5%)
Syncope 17 (13.8%)
ABPR 30 (24.4%)
NSVT 17 (13.8%)
Atrial fibrillation
Paroxysmal 11 (8.9%)
Permanent 7 (5.7%)
Progression to Dilated Cardiomyopathy 9 (7.3%)
ECG
Normal 12 (9.8%)
Abnormal 111 (90.2%)
Other disease
Coronary artery disease 6 (4.8%)
Diabetes 6 (4.8%)
Hypertension 17 (13.8%)Cardiovascular Ultrasound 2009, 7:37 http://www.cardiovascularultrasound.com/content/7/1/37
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and 8 patients (6.5%) had a positive family history of pre-
mature SD. Data analysis revealed that 74 patients
(60.1%) had none risk factor. Twenty four patients
(19.5%) had 1 risk factor, 17 patients (13.8%) had 2 risk
factors, 4 patients (3.25%) had 3 risk factors, and 4
patients (3.25%) had 4 risk factors, while none patient
had 5 risk factors. Twenty five patients (20.3%) had 2 or
more risk factors (Figure 1).
Follow-up
The patients were followed-up for a median period of
34.75 months (range 49.1–81.9). All patients were alive at
the end of follow-up. An implantable cardioverter-defi-
brillator (ICD) was implanted in 10 patients for primary
prevention of SD. Among these patients, 3 had 4 risk fac-
tors, 2 had 3 risk factors, 4 patients had 2 risk factors, and
1 patient had 1 risk factor. The mean follow-up period
after ICD implantation, was 18.6 ± 17.5 months (1 to 48
months). Defibrillator was activated appropriately in 2
patients, by providing antitachycardia pacing for sus-
tained ventricular tachycardia, with the restoration of
sinus rhythm (The risk factors were syncope and NSVT in
one patient, and syncope, NSVT, ABPR, and MWT ≥30
mm in the other patient). The annual incidence of appro-
priate discharges was 10.7%. One patient had an episode
of inappropriate discharge (due to sinus tachycardia).
Stored data were reviewed after all discharges.
Discussion
It is well established that in HCM-patients with a history
of sustained ventricular tachycardia or documented car-
diac arrest the risk of SD is sufficiently high to warrant
prophylactic therapy, irrespective of the presence of other
risk factors [11,16] (Figure 2). Risk stratification in patents
without a history of sustained ventricular tachycardia or
documented cardiac arrest is a big clinical challenge and
sometimes very difficult. Among the various clinical and
echocardiographic variables considered, the simple
model (based on a small number of generally accepted
risk factors) proposed by Elliott et al [4] is, for the time,
the most acceptable. The 5 non-invasive clinical markers
indicating high risk for SD studied by Elliott et al [4] were
family history of premature SD; syncope; NSVT on ambu-
latory (Holter) ECG recordings; ABPR to exercise; and
extreme LV hypertrophy with MWT ≥30 mm. Our study
group of 123 patients with HCM is unique by virtue of
representing a regional cohort from a distinctive region of
Northern Greece. Purpose of this study was the risk strati-
fication of our patients, coming from a representative
Northern Greek population, according to the previous
referred clinical markers.
Table 2: Echocardiographic features of 123 patients with Hypertrophic Cardiomyopathy
Left ventricular end diastolic diameter, cm 4.32 ± 0.79 (2.77 to 7.05)
Left ventricular maximum wall thickness, cm 2.16 ± 0.57 (1.42 to 3.87)
Left ventricular ejection fraction, % 71.7 ± 13 (30 to 90)
Left atrium size, cm 4.09 ± 0.68 (2.24 to 5.90)
Patients with basal gradient ≥30 mmHg 27 (21.9%)
(range 32 to 230 mmHg).
Patients with maximum wall thickness ≥30 mm 15 (12.2%)
Table 3: Medical treatment of 123 patients with Hypertrophic 
Cardiomyopathy
Medication 80 (65%)
b-blocker 59 (47.9%)
verapamil 4 (3.2%)
disopyramide 3 (2.4%)
amiodaron 10 (8.1%)
diltiazem 5 (4%)
warfarin 9 (7.3%)
CEI/ARBs 13 (10.5%)
Statins 13 (10.5%)
Diuretics 8 (6.5%)
Digoxin 2 (1.6%)
Aspirin/clopidogrel 16 (13%)
No Medication 43 (35%)Cardiovascular Ultrasound 2009, 7:37 http://www.cardiovascularultrasound.com/content/7/1/37
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About half of our patients were referred from other centres
for evaluation and treatment, and the other half was firstly
diagnosed and evaluated in our clinic. As a consequence
of this process, our study does not incorporate a substan-
tial degree of patient selection bias. Our data indicates
that a 60% of patients had no risk factors (55% in the
study by Elliott et al [4]). A high percentage (20%) had 2
or more risk factors (12% in the study by Elliott et al [4],
but in this study syncope and family history of premature
SD were considered together as a single risk factor). In the
study by Elliott et al [4] the presence of two or more risk
factors was associated with a 4% to 5% estimated annual
SD risk. Survival analysis was not performed in our study,
since during the short follow-up period there was no any
death among patients, and the objectives of this study was
mainly the identification of the risk factors in our cohort.
Although an ABPR to exercise is considered as a prognos-
tic factor only in patients younger than 40 years of age
[17], this marker was also examined in older patients, in
order to collect homogeneous data in all patients. Addi-
tionally, a history of premature SD was considered posi-
tive if SD was happened before the age of 50 (<40 years in
the study by Elliot et al [4]). The fact that almost 5% of
patients without any risk factors experience sudden death
[4], indicates that other variables, such as subaortic
obstruction, atrial fibrillation and myocardial ischemia,
must be taken into account in the risk stratification proc-
ess.
Conclusion
This study for the first time confirms that, although a 60%
of patients with HCM coming from a regional Greek pop-
ulation are in low risk for SD, a substantial proportion
(almost 20%) carries a high risk for SD justifying prophy-
lactic therapy with amiodaron or ICD implantation.
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